January 31, 2023
Findings from the MOMENTUM phase 3 study show that the use of momelotinib significantly impacts patients with myelofibrosis.
January 17, 2023
Srdan Verstovsek, MD, PhD, discusses the issues faced by patients with cytopenic myelofibrosis.
January 17, 2023
The ability to modify disease in patients with myelofibrosis was signaled in the REFINE study. The combination also displayed positive efficacy and was tolerable.
January 14, 2023
During a Targeted Oncology case-based roundtable event, Rami Komrokji, MD, discussed with participants their approach toward assessing and treating a patient with symptoms possibly indicating primary myelofibrosis.
January 11, 2023
In an interview with Targeted Oncology, Srdan Verstovsek, MD, discussed the potential use of momelotinib as a treatment for patients with myelofibrosis if approved by the FDA in June 2023.
January 04, 2023
During a Targeted Oncology case-based roundtable event, Rami Komrokji, MD, discussed data supporting the use of ruxolitinib and what role it may play in improving long-term outcomes for patients with myelofibrosis. This is the second of 2 articles based on this event.
December 27, 2022
During a Targeted Oncology case-based roundtable event, Rami Komrokji, MD, and participants discussed when to start treatment for patients with myelofibrosis.
December 16, 2022
A more severe symptom burden was seen in patients with isolated thrombocytopenia vs those with isolated anemia, according to findings from the phase 3 PERSIST-1 and PAC203 trials in myelofibrosis.
December 12, 2022
The MOMENTUM trial continues to show positive results for momelotinib fro the treatment of anemic myelofibrosis.
December 12, 2022